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OBJECTIVES: The purpose of this study was to evaluate the
cost-effectiveness of adjuvant trastuzumab treatment of HER2+
early stage breast cancer (ESBC) patients from the perspective of
the Belgian health care authorities. METHODS: An existing
Markov model, comparing 1 year adjuvant trastuzumab treat-
ment to current therapy and simulating disease progression over a
lifetime perspective, was adapted to the Belgian context. The
model included 5Markov states (disease free survival, recurrence,
metastasis, cardiac side effects, death) and three temporary 1-cycle
states preceding respectively the aforementioned recurrence,
metastasis and cardiac side effects states. Transition probabilities
were obtained from the EU registration trial (HERA). Health
beneﬁts were expressed in quality-adjusted life years (QALY)
gained, future beneﬁts were discounted at 1.5%. QALY-weights
were obtained from published literature. Costs were calculated
from the perspective of the Belgian health care budget (year 2005),
future costs were discounted at 3%. Costs were obtained from the
IMS Belgian Hospital Disease Database (longitudinal database,
representative panel of 37 hospitals), from an expert opinion
analysis (6 Belgian oncology centers), and from ofﬁcial data
sources and published literature. A deterministic incremental
cost-effectiveness ratio (ICER) was calculated for 5 different age
categories (<50, 50–59, 60–69, 70–79 and 80 years). Conﬁ-
dence intervals (95% CI) were estimated by probabilistic sensitiv-
ity analyses. Based on the estimated Belgian age distribution of
HER2+ ESBC patients, an overall deterministic ICER for the
Belgian population of treatment eligible patients was calculated.
RESULTS: The ICER for age categories <50, 50–59, 60–69,
70–79 and 80 years was estimated at respectively €6,520 (95%
CI: €3,704–€10,350), €8,363 (95% CI: €4,793–€13,436),
€12,343 (95%CI: €6,636–€20,224), €24,997 (95%CI: €13,708–
€42,908) and €96,150 (95% CI: €53,944–€206,007) per QALY
gained. The ICER for the total Belgian population of treatment
eligible patients was estimated at €10,315 per QALY gained.
CONCLUSION: Adjuvant trastuzumab treatment of HER2+
ESBCpatients is predicted to be cost-effective from the perspective
of the Belgian health care payer.
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OBJECTIVES: To evaluate the cost-effectiveness of docetaxel
versus the once weekly paclitaxel regimen (Pac-1w) and the
nano-particle bound paclitaxel (Nab-Paclitaxel) from the
National Health Service perspective (UK). METHODS: AA
Markov model was developed to estimate the total treatment
related costs and clinical beneﬁts of taxane treatment for MBC
patients over lifetime. Patients moved through health states of
progression-free survival, progression and death. In absence of
head-to-head clinical trials, indirect comparisonsweremade using
Pac-3w as a common comparator in 3 clinical trials (Jones 2005,
Seidman 2004, Gradishar 2005). Adverse events, dose reduction,
G-CSF use, and post-failure treatment were modelled. Costs of
chemotherapy and utility values for health states and adverse
events were obtained from published literature. Costs came from
2005 NHS reference costs and British National Formulary 2006.
Nab-paclitaxel’s per cycle price was assumed to equal docetaxel’s.
Costs and beneﬁts were discounted at 3.5%. Probabilistic sensi-
tivity analyses were conducted. RESULTS: Compared to Pac-1w,
docetaxel yields higher mean health beneﬁts (2.01 vs. 1.73 life
years (LYs) and 1.18 vs. 1.03 quality-adjusted life-years (QALYs))
and costs less than the generic paclitaxel (13,518 vs. 15,008)
therefore permits the NHS to save 5400/LY and 9800/QALY.
Against Nab-paclitaxel, docetaxel produced higher LYs (2.01 vs.
1.62) and QALYs (1.18 vs. 0.96) but at a slightly higher cost
(13,518 vs. 11,640). Docetaxel had an incremental cost-
effectiveness ratio of4900/LYGand8600/QALYagainstNab-
paclitaxel. Given the indirect nature of this analysis, ICERs rely on
many assumptions and are sensitive to hazard ratios and to the
price of treatments. Conﬁdence intervals around the ICERs are
consequently high. CONCLUSION: Based on current evidence
docetaxel is cost-saving compared to generic pac-1w, which is
used but not approved in the UK, and cost effective compared to
Abraxane. Data from ongoing head-to-head clinical studies will
be necessary to reduce the wide conﬁdence intervals.
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OBJECTIVES: To evaluate the cost effectiveness of maintenance
rituximab therapy in the treatment of relapsed/refractory follicu-
lar NHL compared to observation alone. METHODS: A health
state transition model with 3 health states (progression-free,
progressive disease and death) was created utilising the Kaplan
Meier progression-free and overall survival data from the
EORTC20981 registration trial for the ﬁrst 24 months of the
model. A Weibull parametric function was then used to extrapo-
late survival for the remaining lifetime time-horizon of the
model, selection of the parametric function was based on good-
ness of ﬁt, relative to alternative parametric functions. The
assumed treatment effect of rituximab was limited to 5 years in
the model thereafter rituximab patients subsequently had a
monthly risk of death and disease progression equivalent to the
observation group. Patient characteristics were assumed equiva-
lent to the EORTC20981 study. QALYs were derived using
utility scores from a UK survey of over 200 follicular lymphoma
patients using the EQ-5D instrument, valued from the societal
perspective. Post protocol treatments were included, estimated
directly from the EORTC20981 study, routine patient monitor-
ing, drug administration and adverse event costs were also
included. RESULTS: Rituximab maintenance was associated
with an additional 0.89 QALYs compared to the observation arm
and total costs were 6886 higher in the maintenance arm. The
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resulting incremental cost per QALY of 7721 demonstrated
that maintenance therapy with rituximab when compared to
observation was cost-effective. The cost per QALY was very
robust when subject to extensive one-way and probabilistic sen-
sitivity analysis. Probabilistic sensitivity analyses indicated that
the likelihood of the ICER being below 10,000 was 90%.
CONCLUSION: From the perspective of UK NHS, maintenance
rituximab when compared to observation alone for the treatment
of relapsed/refractory follicular NHL patients responding to
induction therapy is a highly cost-effective treatment.
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OBJECTIVES: In Hungary the standard therapy in the adjuvant
treatment of stage III colon cancer is the DeGramont-protocol, a
combination of 5-ﬂuorouracil and leucovorin. In the MOSAIC
trial the addition of oxaliplatin (FOLFOX4) improved the efﬁcacy
of the standard therapy in this patient group. The aim of our study
was to evaluate the cost-effectiveness of FOLFOX4 compared to
standard therapy in Hungary.METHODS: The cost-utility analy-
sis of the FOLFOX4 therapy was based on theMOSAIC trial. The
efﬁcacy data of the MOSAIC trial was extrapolated for lifetime,
while utilities values were incorporated from published sources.
Age and gender speciﬁc general mortality rates and utilities were
derived from epidemiology data of the Hungarian population and
published utilities based on the EQ-5D questionnaire. The analy-
sis was accomplished from payer perspective. Thus, only direct
medical costs were taken into account. Resource use was based on
Hungarian treatment patterns and unit costs. Costs and outcomes
were discounted at 5%. Cost-effectiveness was measured in terms
of incremental cost per quality-adjusted life year saved (QALY),
incremental cost per disease-free years (DFY) and incremental
cost per life-years saved (LYS). One-way sensitivity analysis
was employed. RESULTS: Compared to DeGramont therapy,
FOLFOX4 resulted in an additional 0.455 QALY, 0.531 LYS,
0.958 DFY andHUF 1,310,064 (5,240€) per patient. The cost for
one QALY was HUF 2,880,342 (11,521€), while for one DFS and
LYS was HUF 1,367,712 (5,471€) and HUF 2,468,660 (9,875€),
respectively. The results were most sensitive to discount rate,
general population data and the cost of chemotherapy.CONCLU-
SION: Based on the possible thresholds in Hungary, and the
€20,000/QALY quoted in countries of the EU zone, FOLFOX4 is
a cost-effective strategy inHungary for the postoperative adjuvant
treatment of patients with stage III colon cancer compared to the
DeGramont protocol.
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OBJECTIVES: The aim of the study was to analyze the cost-
effectiveness of sunitinib malate, a novel cancer treatment, as a
second-line therapy for metastatic renal cell carcinoma (mRCC)
after ﬁrst-line cytokine treatment compared with current Finnish
treatment practice. Cytokine therapy is currently the standard
ﬁrst line treatment for mRCC. Until recently, treatments with
proven efﬁcacy after the failure of ﬁrst line cytokine therapy have
not been available. METHODS: Information for analyses was
gathered from clinical trials, the literature and patient records
from two Finnish university hospitals. Clinical experts treating
mRCC-patients in Finland provided the information on current
practices for the sunitinib treatment. A comprehensive probabi-
listic decision-analytic model was developed using WinBUGS
software to estimate the cost-effectiveness and expected value
of perfect information (EVPI) of sunitinib malate. An EVPI
approach was used to estimate the expected costs of decision
uncertainty. A societal perspective was assumed in all analyses to
avoid suboptimal decisions. RESULTS: The Kaplan-Meier sur-
vival estimates after cytokine failure for local patients (n = 39)
were 3.8 months (95% CI, 2.16–5.51) and 1.4 months (95% CI,
0.7–2.17) for overall and progression-free survival, respectively.
When compared to the current Finnish treatment practice, suni-
tinib prolonged life expectancy by 1 year and resulted in a
progression-free time of 6.3 months and in 0.7 QALYs gained.
Over a ﬁve-year time period, an incremental cost-effectiveness
ratio (ICER) of 42,877€ per QALY was obtained. Sunitinib was
estimated to have an 88% probability of being cost-effective at
the willingness-to-pay level of 45,000€/QALY. The population
EVPI for the decision between sunitinib-treatment and current
Finnish treatment practice was 607,000€ at a willingness-to-pay
level of 42,500€. CONCLUSION: Sunitinib malate results in
improved survival and is potentially cost-effective as a second-
line treatment of mRCC compared to the current clinical practice
used in Finnish hospitals.
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OBJECTIVES: Maintenance therapy with rituximab has shown
signiﬁcant improvements in overall survival and progression-free
survival (PFS) when compared with observation in patients with
relapsed/refractory follicular lymphoma (van Oers et al., 2006).
The primary objective of this analysis was to estimate the incre-
mental cost-efectiveness ratio (ICER) of rituximab maintenance
therapy versus observation alone, based on data from the
EORTC 20981 study. METHODS: Rituximab maintenance
therapy (375 mg/m2 every 3 months) was evaluated using a
Markov model. All patients entered in the model following
response to CHOP chemotherapy +/- rituximab as induction
therapy. PFS and Overall Survival (OS) following rituximab
maintenance were extrapolated from 2-year Kaplan-Meier
curves from the study data using a parametric approach. Cox-
Snell and deviance residuals were analysed. Quality-of-life utility
values were derived from a study of 165 patients using the
EQ-5D questionnaire. Direct annual medical costs including
adverse events, drug acquisition, administration and preparation
were estimated accordingly to a Delphi panel with Brazilian
haematologists. Costs were reported in 2007 Brazilian Reais.
Both costs and outcomes were discounted at 3.5% rate according
to NICE/UK recommendation. In order to assess uncertainty,
probabilistic sensitivity analyses were also performed. A lifetime
horizon and a payer perspective in Brazil were adopted.
RESULTS: Rituximab maintenance resulted in a gain of 1.79
QALYs (5.96 vs. 4.17) at an incremental cost of R$57,595 The
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